FLT3 and diffuse large B-cell lymphoma: The data suggest first that baseline nDNA in DLBCL gives additional prognostic information over LDH and early changes during therapy may predict subsequent outcome in FL, second, that rises in CK18 on chemotherapy give early warning of epithelial toxicity and third, that substantial elevation in FLT3 ligand identifies patients at risk of NPS.